Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.18

-1.4%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (28405)	2/26/1999 12:55:00 PM
From: schadenfreude	Read Replies (2) of 32384

Competition in CTCL biz.yahoo.com "Recently, a drug was approved by the FDA for CTCL. However, approval is limited to a subset of patients whose malignant cells express the CD25 component of the Interleukin-2 (IL-2) receptor. Only about 50 percent of the patient population expresses this receptor, and in these trials 30 percent of the patients with the IL-2 receptor responded. Nipent acts by blocking the enzyme adenosine deaminase in the cells and does not require the presence of surface receptors; therefore, it can be used in the management of all patients."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next